Background: Omalizumab has been shown to be effective in treating chronic spon-
| INTRODUCTION
Chronic spontaneous urticaria (CSU) is a common disease with a point prevalence of 1% of the general population. 1 Patients manifest with hives on most days for a period of at least 6 weeks. The disease is often accompanied by angioedema and tends to be cyclical in nature, with spontaneous disappearances and frequent relapses. 2 In most cases, no underlying disease or allergy can be found. 3 Chronic spontaneous urticaria treatment relies mainly on secondgeneration antihistamines and is purely symptomatic. While some patients respond to standard-dose second-generation antihistamines, in others off-label (for CSU) treatments with high-dose H1-antihistamines, leukotriene receptor blocking agents, cyclosporine A, or systemic corticosteroids are needed. 4, 5 Based on several randomized controlled trials, 6-8 the monoclonal anti-IgE antibody omalizumab was recently licensed for the treatment of antihistamine-resistant CSU. 9 The mechanism of action of omalizumab in CSU is still not fully understood. Omalizumab binds selectively to free IgE in plasma, inhibits its binding to FceRI receptors on the surface of mast cells and basophils, and reduces the number of FceRI receptors on basophils in atopic patients 10, 11 and those with CSU. 12, 13 A significant reduction in FceRI receptor density on the surface of circulating basophils has been found as early as 1 week after the administration of omalizumab. 14 In contrast, a decrease in FceRI receptor density on mast cells may occur later. 11 The role of basophils in CSU is still debated, 15 but basophils may be an accessible and relevant model to analyse the effect of omalizumab on FceRI expression and on the level of basophil activation.
About half of CSU patients have autoantibodies against FceRI, few against IgE. 16, 17 Other autoimmune markers such as IgE and IgG antibodies against thyroid peroxidase are frequently found. 7 Sera of CSU patients can activate the resting basophils of normal donors to release histamine and up-regulate the activation markers CD63 and CD203c. 18, 19 The basophil activation test with donor basophils (CU-BAT) involves measuring CD63 up-regulation as an activation marker and is already established as a specific, sensitive, and safe in vitro assay to detect functional autoantibodies. [18] [19] [20] [21] In addition, the FceRI receptor density itself might be another important parameter for the quantification of mast cell and basophil "releasability" and therefore a good in vitro surrogate marker for their reactivity.
To gain insight into the pathophysiology of some forms of CSU and the mode of action of omalizumab, we evaluated the effect of 2 | METHODS
| Study design
In a monocentric, double-blind, randomized, placebo-controlled trial,
we investigated the mechanism of action of omalizumab in antihistamine-resistant CSU over a period of 7 months, between September 2012 and April 2014. Thirty patients diagnosed with CSU were recruited and randomly assigned to 2 groups in a 2:1 ratio to receive either omalizumab (n = 20) or placebo (n = 10). Omalizumab (Xolair â ) was administered in 4 monthly treatments at a fixed subcutaneous dose of 300 mg as currently licensed. 6, 23 Before the first administration, disease activity was assessed and documented over a 4-week period with the urticaria activity score (UAS), followed by the 16-week treatment period with 4 injections of omalizumab/ placebo. Two months after the last injection, a final study visit to follow up treatment efficacy and study outcomes took place.
The study was approved by the local ethics committee and by Swissmedic, the Swiss agency for therapeutic products. 
| Study population
Patients between the ages of 18 and 70 with CSU were included in the study if they met the following criteria: symptoms for at least a) The FceRI density on basophils was measured at randomization and on the day of the first treatment, and thereafter at 1 week, 1 and 3 months, and 2 months after stopping treatment. The
FceRI receptor density was assessed by QIFIKIT (Dako-Cytomation, Glostrup, Denmark) according to the instructions of the manufacturer. 24 For each quantification, 500-1000 basophils were acquired using CCR3 basophil-specific staining. FceRI receptor density was defined according to the standard curve using beads with ascending predefined receptor densities. . 21 The donors were previously screened for reactivity to negative and positive controls as well as for basophil activation with different IL-3 concentrations. All serum samples
were immediately stored at À20°C in aliquots to avoid repetitive freeze-thaw cycles.
| Patient assessments
All participants were required to document their symptoms once daily for 1 month using the urticaria activity score. 26 Medications taken were documented on their study questionnaires.
| Study endpoints
The primary endpoint of the study was the FceRI receptor density change on basophils during the first 12 weeks of treatment with omalizumab and 2 months after treatment.
Secondary endpoints included comparison of basophil releasibility
with and without IL-3 incubation at 3 time-points (baseline, 1 week, and 3 months); comparison of CU-BAT at baseline and 3 months; and change in the weekly urticaria activity score (UAS7) at baseline, 3 months, and 5 months. We evaluated the proportion of patients with a UAS7 of ≤6, a UAS7 of 0, and an itch severity score (ISS) of 0.
We summarized the proportion of patients who used H1-and H2-antihistamines, montelukast, and prednisolone (Table S3) , and coded adverse events using the medical dictionary for regulatory activities (MeDRA) and their corresponding preferred terms and assigned body systems (Table S1 ).
| Post hoc analysis
Recently, Gericke et al. 22 observed that the presence of autoreactive serum components predicted the response time to omalizumab treatment. We therefore performed a post hoc analysis to identify differences in FceRI receptor density, autoreactive serum components (measured by CU-BAT), and total IgE in omalizumab partial/ non-responders, early responders, and slow responders. Based on a previous report, 22 we divided all study patients into 4 groups: placebo; partial/non-responder, defined as a UAS7 >6 at 3 months or a reduction in UAS7 to ≤6 or less at 3 months compared to baseline; early responder, defined as a treatment response within 8 days, with the first day of response determined as the first day of UAS7 <6;
and slow responder, defined as a treatment response after 8 days but UAS7 <6 at 3 months. For each of these groups, we compared FceRI receptor density, CU-BAT results, and total IgE at baseline, and calculated whether there was a difference in FceRI density and CU-BAT between baseline and 3 months.
| Sample size determination
A biological effect for the primary outcome was determined to be a difference of FceRI receptor density of 45 000 per basophil, assuming a SD of 40 000 Fc-IgE per basophil. A power of 80%, a 2-sided P-value of .05, and 2:1 randomization resulted in an overall sample size of 30 patients, with 20 in the active group and 10 in the placebo group.
| Analysis of primary, secondary, and other efficacy endpoints
The primary endpoint, FceRI receptor density, was analysed using generalized estimation equations (GEE) with a negative binomial distribution family, log link, and robust standard errors due to strong skewness and heteroscedasticity when using mixed-effects linear models. Treatment group and baseline receptor density were included as fixed effects. The mean of the 2 pretreatment visits was taken as the baseline receptor density. We report the ratio between treatments, with a ratio <1 indicating a reduction in receptor density.
We used the same methods to analyse FceRI receptor density at each follow-up time.
Analysis of the primary endpoint followed the intention-to-treat (ITT) principle. Missing primary endpoint values were imputed by multiple imputation techniques using sequential chained equations based on baseline characteristics. Altogether, 12 of 150 (8.0%) FceRI receptor measurements were missing, the majority at the last visit.
As a sensitivity analysis, we also performed the main analyses on the per-protocol population. Twenty-four patients who completed all treatments according to the protocol were included.
Secondary endpoints are summarized using descriptive statistics.
Odds ratios (OR) for the UAS7 and ISS were calculated using penalized logistic regression by Firth's method. 27 Analysis was performed using Stata 13.1 and 14. 28 For all analyses we report estimates and 95% confidence intervals (CI) when relevant. Descriptive statistics report mean and standard deviation (SD)
for continuous and normally distributed data or median and interquartile range (IQR) for non-normally distributed or highly skewed data. Count and percentages are reported for binary data.
3 | RESULTS
| Study patients
A total of 77 patients were screened, 41 of whom were excluded: Most baseline characteristics (age, weight, BMI) did not differ between the placebo and omalizumab groups ( There were 8 partial/non-responders, 7 early responders, and 2 slow responders in the omalizumab group; 3 patients who dropped out could not be classified.
| FceRI receptor density
At baseline, no significant differences in FceRI receptor density were found between the 2 groups ( Figure 2 , Table S2 ). | 199 P = <.001) and was still low at 2 months after the last injection (93.81 AE 56.50 9 10³ vs 21.09 AE 15.23 9 10³, respectively, P = .002).
| Basophil releasability
Regarding basophil releasability, expressed as Log10 of the anti-IgE
(not omalizumab) concentration resulting in half-maximal activation of basophils (LC50), no significant difference in the LC50 value could be found between the 2 groups at the start of treatment (with or wthout IL-3). Treatment did not result in a consistent change of releasibility (Table 2A) . Interestingly, the basophil releasability measured with IL-3 coincubation decreased in the omalizumab group during the study (higher values indicate lower basophil releasability).
However, due to the small sample size, statistical significance cannot be shown.
| Effect of omalizumab on serum factors
Patient serum was incubated twice with third-party donor basophils Treatment did not significantly affect the activity of these serum factors (Table 2B ).
| CSU activity
The UAS7 was summed for a week before each study visit, and the proportions of patients with mild (UAS7 of ≤6) or no symptoms (UAS7 = 0) were evaluated. The proportion of patients with no itching (ISS = 0) in the week before the corresponding visit was also assessed (Table 3) .
We observed no significant differences at baseline in UAS7 ≤6 Values are mean AE SD for continuous variables, or median and interquartile ranges (IQR) for nonnormally distributed or highly skewed variables. Categorical variables reported as n (%). ≤6 and ISS = 0 showed no significant difference between the placebo and omalizumab groups.
| Post hoc analysis
In a post hoc analysis, we classified all study patients into 4 groups:
placebo, partial/non-responder, early responder, and slow responder (Table 4) Confidence intervals from penalized logistic regressions. Urticaria activity score (UAS7) was summed for a week before the above times and evaluated for the proportions of patients with mild (UAS7 ≤ 6) or no symptoms (UAS7 = 0). ISS was evaluated for the proportion of patients with no itching (ISS = 0) in the week before the corresponding visit. Odds ratios (OR) for the UAS7 and ISS were calculated. *At time of study inclusion, all patients had UAS7 >6.
T A B L E 2 (A) Basophil releasability after stimulation with anti-IgE (not omalizumab). (B) Incubation of patient serum with donor basophils (CU-BAT)
We found that treatment with omalizumab resulted in a rapid and significant reduction in FceRI density on basophils, which is consistent with previous studies 10, 11, 14 and confirms the results of Deza et al. 12 and Metz et al. 13 This reduction was observed as soon as While CSU is a mast cell-driven disease, our experimental approach relied on basophils due to their better accessibility and the assumptions that (i) basophils play a relevant role in the pathogenesis of CSU, 13, 19 and (ii) analysis of basophil activity is a relevant model for changes of omalizumab-induced mast cell activity. While omalizumab does not lead to a significant reduction in autoreactive serum components, its effect might rely on cellular changes. It is well known that circulating basophils are recruited into skin lesions in CSU. [32] [33] [34] It is possible that omalizumab decreases the ability of basophils to migrate into the skin, for example by altering their chemokine receptor repertoire. Consistent with this hypothesis, Metz
Comparison of FceRI density (receptors per basophil), incubation of patient serum on donor basophils (CU-BAT: CD63%), and total IgE (kU/L) in partial/non-responders, slow responders, and early responders We compared different biological effects among the patients classified into 4 groups (placebo, partial/non-responder, slow responder, and early responder) using the chi-squared test and the non-parametric Kruskal-Wallis rank test as appropriate. We compared the FceRI receptor density, CU-BAT results (ie CD63 change), and total IgE values at baseline, and calculated whether there was a difference of FceRI receptor density and CU-BAT between baseline and 3 months.
et al. 13 showed a decrease in the number of FceRI+ skin cells under omalizumab treatment.
Our study population was heterogeneous: 6 of our 30 patients had a changing disease course with only mild symptoms at baseline compared to the time of study inclusion. This reflects the natural course of CSU, which is characterized by intermittent remissions, and might explain the nonsignificant differences in various endpoints. Furthermore, as we intended to study patients with severe forms of CSU, there were 8 partial/non-responders. This probably influenced the study outcomes, but gave us the opportunity to identify differences between slow, early, and partial/non-responders.
CSU tends to remit spontaneously, and thus far no sustained disease-modifying effect of omalizumab has been documented after the medication is discontinued. Furthermore, the response time after initiating omalizumab treatment varies greatly. FceRI density on basophils, CU-BAT, and total IgE might be appropriate parameters to predict response time and disease course under omalizumab. Assessing these factors before initiating treatment with omalizumab could help differentiate between early, slow, and partial/non-responders. In particular, low FceRI density and/or high CU-BAT at baseline might predict whether a patient will be a partial/non-responder. Practically speaking, it would be even easier to determine the total IgE value at baseline, as it corresponds to FceRI density, meaning that a low total IgE predicts a low FceRI density.
In patients who respond to omalizumab, treatment discontinuation is necessary to reveal the underlying disease status. As omal- 
